PepGen Inc. ( (PEPG) ) just unveiled an update.
On March 27, 2025, PepGen Inc. announced the appointment of Mitchell Finer, Ph.D., and Lisa Wyman to its Board of Directors, expanding the board from six to eight members. Dr. Finer, with extensive experience in genetic therapies and executive roles in various biotechnology companies, and Ms. Wyman, known for her expertise in scaling manufacturing and navigating global regulatory agencies, are expected to strengthen PepGen’s board as the company advances its mid-stage clinical trials and continues to develop its EDO platform.
More about PepGen Inc.
PepGen is a clinical-stage biotechnology company focused on developing next-generation oligonucleotide therapies aimed at transforming the treatment of severe neuromuscular and neurological diseases. The company leverages its Enhanced Delivery Oligonucleotide (EDO) platform, which utilizes cell-penetrating peptides to enhance the uptake and activity of conjugated oligonucleotide therapeutics.
YTD Price Performance: -60.74%
Average Trading Volume: 2,957,170
Technical Sentiment Signal: Buy
Current Market Cap: $48.38M
For a thorough assessment of PEPG stock, go to TipRanks’ Stock Analysis page.